Molecular and clinical responses observed across multiple cancer types, including those with high replication stress Predictable and manageable safety profile with reliable pharmacokinetics offers combination flexibility and continuous and intermittent dosing regimens Initial Phase 2 data from ongoing trial for ART0380 in platinum resistant ovarian cancer is expected for the gemcitabine combination in H1 2025 and for the irinotecan combination in ATM deficient cancers in H2 2024 CAMBRIDGE, United Kingdom and NEW YORK, Oct.

在多种癌症类型中观察到的分子和临床反应，包括那些具有高复制应力的可预测和可管理的安全性和可靠的药代动力学提供了组合的灵活性和连续和间歇给药方案ART0380在铂类耐药卵巢癌中正在进行的试验的初始阶段2数据预计将在2025年H1的吉西他滨组合和ATM缺陷的伊立替康组合H2 2024年的癌症英国剑桥和纽约，10月。

23, 2023 (GLOBE NEWSWIRE) -- Artios Pharma Limited (Artios), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, presented promising monotherapy data from the Phase 1/1b portion of the ongoing Phase 1/2a study (NCT04657068) of its ataxia telangiectasia and Rad-3 related (“ATR”) kinase inhibitor ART0380 in advanced or metastatic solid tumors as part of a poster presentation at the European Society of Medical Oncology Congress (ESMO) 2023.

232023（GLOBE NEWSWIRE）-Artios Pharma Limited（Artios），一家由DNA损伤反应（“DDR”）药物开发先驱领导的临床阶段生物技术公司，作为其共济失调毛细血管扩张症和Rad-3相关（“ATR”）激酶抑制剂ART0380在晚期或转移性实体瘤中正在进行的1/2a期研究（NCT04657068）的1/1b期部分提供了有希望的单一疗法数据，作为海报的一部分在欧洲医学肿瘤学会大会（ESMO）2023上发表。

ART0380 is a clinically advanced, oral, highly potent, and selective ATR inhibitor with best-in-class potential. The Phase 1/1b portion of the trial presented at ESMO assessed the safety and tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ART0380 monotherapy in patients with advanced or metastatic solid tumors.

ART0380是一种临床先进的口服高效选择性ATR抑制剂，具有一流的潜力。在ESMO上进行的试验的1/1b期部分评估了ART0380单药治疗晚期或转移性实体瘤患者的安全性和耐受性，药代动力学（PK），药效学和初步疗效。

The patient population was enriched for cancers harboring DNA damage response deficiencies as identified by the Artios DcoDeR platform (n = 49). Dr. Niall Martin, Chief Executive Officer at Artios, said: “As a master regulator of replication stress, ATR inhibition can increase DNA damage and powerfully suppress tumor growth across broad cancer types harboring genetic defects.

根据Artios DcoDeR平台（n=49）确定，患者人群富含DNA损伤反应缺陷的癌症。Artios首席执行官Niall Martin博士说：“作为复制压力的主要调节者，ATR抑制可以增加DNA损伤，并有力地抑制具有遗传缺陷的广泛癌症类型的肿瘤生长。

However, durability and long-term use with first-gener.

但是，第一代的耐久性和长期使用。